Physician profile
Daniel Daugherty, II
NPI 1336630383
$4,616.62
in general payments reported to CMS, 2019-2025
18 companies · $467 in 2025
The $467 reported for 2025 was more than what 75% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $150 · 2021: $486 · 2022: $630 · 2023: $708 · 2024: $473 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,570 · Entertainment: $76.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,570.27 |
| Entertainment | $76.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,517.20 | 2019-2025 | Precision7, Precision 1, Total30 |
| Coopervision INC. | $474.71 | 2019-2025 | Clariti Contact Lens, Myday Contact Lens, Misight Contact Lens |
| Johnson & Johnson Vision Care, INC. | $411.37 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $232.88 | 2022-2025 | Infuse, Miebo, Scoutpro Osmolarity System |
| Sun Pharmaceutical Industries INC. | $130.33 | 2019-2025 | Cequa |
| Abb Con-Cise Optical Group LLC | $126.88 | 2022-2025 | Contact Lens, Spectacle Lenses |
| Aerie Pharmaceuticals, INC. | $121.84 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $120.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $113.78 | 2021-2022 | |
| Oyster Point Pharma, INC. | $105.20 | 2023-2025 | Tyrvaya, Ryzumvi |
| Optos, INC. | $76.71 | 2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biotissue Holdings INC. | $58.26 | 2020-2024 | |
| Abbvie INC. | $32.13 | 2022 | |
| Kala Pharmaceuticals, INC. | $28.85 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.79 | 2023 | Xarelto |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $18.53 | 2025 | Iyuzeh |
| Merck Sharp & Dohme LLC | $18.25 | 2025 | Capvaxive, Enflonsia, Vaxneuvance |
| Visioneering Technologies, INC. | $9.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Daugherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.